Evidence map›Paper›PMID 25348169›Full record

ReviewNature reviews. Urology2014

Looking forward, looking back-10 years in urology.

Maarten Albersen, Rufus Cartwright, Peter Choyke, S Larry Goldenberg, Howard Goldman, Nathan Lawrentschuk, W Marston Linehan, Declan Murphy, Harris Nagler, Peter Scardino and 3 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Urology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Maarten AlbersenDepartment of Urology, University Hospitals Leuven, Herestraat 49, Leuven 3000, Belgium.
Rufus CartwrightImperial College London, Institute of Reproductive and Developmental Biology, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.
Peter ChoykeThe Molecular Imaging Program, NCI, NIH, 10 Center Drive, Building 10, Room B3B69, Bethesda, MD 20892 USA.
S Larry GoldenbergUniversity of British Columbia, Department of Urologic Sciences, Level 6, 2775 Laurel Street, Vancouver, BC V5Z 1M9, Canada.
Howard GoldmanGlickman Urological and Kidney Institute, The Cleveland Clinic, Q10-1, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Nathan LawrentschukUniversity of Melbourne, Department of Surgery and Ludwig Institute for Cancer Research, Austin Hospital, Suite 5, 210 Burgundy Street, Heidelberg, VIC 3084, Australia.
W Marston LinehanUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Building 10, CRC Room 1-5940, Bethesda, MD 20892, USA.
Declan MurphyDivision of Cancer Surgery, Peter MacCallum Cancer Centre, East Melbourne, VIC 3003, Australia.
Harris NaglerBeth Israel Medical Center, 10 Union Square East, Suite 3A, New York, NY 10003, USA.
Peter ScardinoMemorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Linda ShortliffeDepartment of Urology, S287, 300 Pasteur Drive, Stanford, CA 94305-5118, USA.
Arnulf StenzlDepartment of Urology, University Clinic of Urology, Hoppe-Seyler-Strasse 3, 72076 Tübingen, Germany.
Dan TheodorescuUniversity of Colorado Comprehensive Cancer Center, MS F-434, 13001 East 17th Place, Aurora, CO 80045, USA.

Funding

Molecular Therapeutics of Kidney Cancer: VHL Gene and Fumarate Hydratase GeneZIABC011038 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$29.8M
Molecular Therapeutics of Kidney Cancer: MET Gene and BHD GeneZIABC011043 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$20.9M
Clinical Studies of the Molecular Genetic Basis of Kidney CancerZIABC011028 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$17.9M
Clinical Nursing and Data Management CoreZIDBC011089 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$17.4M
Medical Research Council G1100377
6 · The paper itself

Abstract

When Nature Reviews Urology launched in 2004, the field of urology was vastly different to that which we work in today, and the past 10 years have seen the field change immensely. As a specialty on the forefront of cutting-edge innovation, urologists are often the first to embrace new technologies and ideas. In this Viewpoint, members of the Nature Reviews Urology advisory board were asked what they thought was the most important change, issue or innovation in urology in the past 10 years, and what they expected to be the most important in the next decade. Here are their opinions.

Indexed as

Antineoplastic AgentsBiomedical ResearchDiagnostic ImagingEvidence-Based MedicineHigh-Throughput Nucleotide SequencingHumansInventionsMinimally Invasive Surgical ProceduresMolecular Targeted TherapyReproductive Techniques, AssistedRobotic Surgical ProceduresSuburethral SlingsUrologic DiseasesUrologyAntineoplastic Agents

Identifiers

PMID25348169

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.